Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287450
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-01
First Post:
2024-02-22
Brief Title:
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults
Sponsor:
Shenzhen Shenxin Biotechnology Co Ltd
Organization:
Shenzhen Shenxin Biotechnology Co Ltd
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled Dose-Ranging Study to Evaluate the Safety Reactogenicity and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine IN006 in Healthy Adult Participants
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the safety tolerability and immunogenicity of a single injection of up to 4 dose levels of IN006 in younger adults and 3 dose levels of IN006 in older adults of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None